Clinical Trials Logo

Clinical Trial Summary

The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00347425
Study type Interventional
Source Solvay Pharmaceuticals
Contact
Status Completed
Phase Phase 3
Start date December 2006
Completion date February 2008

See also
  Status Clinical Trial Phase
Completed NCT00292409 - A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices Phase 3
Active, not recruiting NCT01804920 - D-Serine Treatment For Tardive Dyskinesia N/A